Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients

Mancari, Rosanna
Signorelli, Mauro
Carinelli, Silvestro
De Ponti, Elena
Sesana, Silvia
Corso, Silvia
Chiappa, Valentina
Colombo, Nicoletta
Lissoni, Andrea Alberto
GADDUCCI, ANGIOLO

January 2014

Objective About 50-60% of patients with stage I-II uterine leiomyosarcoma (ULMS), primarily treated ...

Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.

Cojocaru, E
Palahepitiva Gamage, G
Butler, J
Barton, DP
Thway, K
Fisher, C
Messiou, C
Miah, AB
Zaidi, S
Gennatas, S
Benson, C
Huang, P
Jones, RL

May 2021

Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...

Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

Asano, Hiroshi
Isoe, Toshiyuki
Ito, Yoichi M.
Nishimoto, Naoki
Watanabe, Yudai
Yokoshiki, Saki
Watari, Hidemichi

March 2022

Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Althou...

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Pellanda, Alessandra Franzetti
De Bari, Berardino
Deniaud-Alexandre, Elisabeth
Krengli, Marco
Van Houtte, Paul
Richetti, Antonella
Villà, Salvador
Goldberg, Hadassah
Szutowicz-Zielińska, Ewa
Bolla, Michel
Rutten, Heidi
Van Eijkeren, Marc
Poortmans, Philip
Henke, Guido
Anacak, Yavuz
Chan, Steve
Landmann, Christine
Kirkove, Carine
Scandolaro, Luciano
Bernier, Jacques
Mirimanoff, René-Olivier
Ozsahin, Mahmut

January 2017

Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study.

Pellanda, A.F.
De Bari, B.
Deniaud-Alexandre, E.
Krengli, M.
Van Houtte, P.
Richetti, A.
Villà, S.
Goldberg, H.
Szutowicz-Zielińska, E.
Bolla, M.
Rutten, H.
Van Eijkeren, M.
Poortmans, P.
Henke, G.
Anacak, Y.
Chan, S.
Landmann, C.
Kirkove, C.
Scandolaro, L.
Bernier, J.
Mirimanoff, R.O.
Ozsahin, M.

December 2017

Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...

An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center

Ulaş Solmaz
Levent Dereli
Gülşah Selvi Demirtaş
Atalay Ekin
Emre Mat
Cenk Gezer
Pınar Solmaz Hasdemir
Sevil Sayhan
Muzaffer Sancı
Niyazi Aşkar

September 2015

Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prog...

An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center [Yüksek hacimli bir kanser merkezinde uterin leiomyosarkomlu 37 olgunun analizi]

Solmaz U.
Dereli L.
Demirtaş G.S.
Ekin A.
Mat E.
Gezer C.
Hasdemir P.S.
Sayhan S.
Sancı M.
Aşkar N.

January 2015

Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and progn...

Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma

Loizzi V
Cormio G
Nestola D
Falagario M
Surgo A
Camporeale A
Putignano G
Selvaggi L.

January 2011

Objectives: It was the aim of this study to evaluate clinicopathological characteristics and prognos...

Prognostic factors in early-stage leiomyosarcoma of the uterus.

Pelmus, M.
Penault-Llorca, F.
Guillou, L.
Collin, F.
Bertrand, G.
Trassard, M.
Leroux, A.
Floquet, A.
Stoeckle, E.
Thomas, L.
MacGrogan, G.

January 2009

Uterine leiomyosarcomas (LMSs) are rare cancers representing less than 1% of all uterine malignancie...

Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies

Casarin J.
Ghezzi F.
Lembo A.
Artuso V.
Schivardi G.
Galati E. F.
Ambrosoli A. L.
Bogani G.
Multinu F.
Cromi A.

January 2023

Background and Methods: Uterine leiomyosarcomas (uLMS) are rare malignant tumors, often incidentally...

Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin

Oosten, Astrid
Seynaeve, Caroline
Schmitz, Paul
Bakker, Michael
Verweij, Jaap
Sleijfer, Stefan

December 2009

textabstractAlthough leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs)...

Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years\u27 clinical experience from a tertiary care center in Pakistan

Khan, Saqib Raza
Soomar, Salman Muhammad
Asghari, Tamana
Ahmed, Arsalan
Moosajee, Munira

June 2023

Background: Uterine sarcoma is an uncommon aggressive malignancy. Optimal management and prognostic ...

Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors : the result of a retrospective study of 423 cases of uterine sarcoma

Oláh, K. S.
Dunn, Janet A.
Gee, H.

July 1992

Objective To determine the survival data for the various tumour types of uterine sarcoma and determi...

Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study

Bizzarri N
Ghirardi V
Di Fiore GLM
De Iaco P
Gadducci A
Casarin J
Perrone AM
Pasciuto T
Scambia G
Fagotti A

January 2019

Uterine leiomyosarcoma (uLMS) represents a rare gynecological malignancy with high incidence of recu...

Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases.

Wang, Wei-Lien, MD
Soslow, Robert A
Hensley, Martee
Asad, Haider, MD
Zannoni, Gian Franco
de Nictolis, Michele
Branton, Philip
Muzikansky, Alona
Oliva, Esther

April 2011

Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5...

Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients

Mancari, Rosanna
Signorelli, Mauro
Carinelli, Silvestro
De Ponti, Elena
Sesana, Silvia
Corso, Silvia
Chiappa, Valentina
Colombo, Nicoletta
Lissoni, Andrea Alberto
GADDUCCI, ANGIOLO

January 2014

Objective About 50-60% of patients with stage I-II uterine leiomyosarcoma (ULMS), primarily treated ...

Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.

Cojocaru, E
Palahepitiva Gamage, G
Butler, J
Barton, DP
Thway, K
Fisher, C
Messiou, C
Miah, AB
Zaidi, S
Gennatas, S
Benson, C
Huang, P
Jones, RL

May 2021

Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...

Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

Asano, Hiroshi
Isoe, Toshiyuki
Ito, Yoichi M.
Nishimoto, Naoki
Watanabe, Yudai
Yokoshiki, Saki
Watari, Hidemichi

March 2022

Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Althou...

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Pellanda, Alessandra Franzetti
De Bari, Berardino
Deniaud-Alexandre, Elisabeth
Krengli, Marco
Van Houtte, Paul
Richetti, Antonella
Villà, Salvador
Goldberg, Hadassah
Szutowicz-Zielińska, Ewa
Bolla, Michel
Rutten, Heidi
Van Eijkeren, Marc
Poortmans, Philip
Henke, Guido
Anacak, Yavuz
Chan, Steve
Landmann, Christine
Kirkove, Carine
Scandolaro, Luciano
Bernier, Jacques
Mirimanoff, René-Olivier
Ozsahin, Mahmut

January 2017

Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study.

Pellanda, A.F.
De Bari, B.
Deniaud-Alexandre, E.
Krengli, M.
Van Houtte, P.
Richetti, A.
Villà, S.
Goldberg, H.
Szutowicz-Zielińska, E.
Bolla, M.
Rutten, H.
Van Eijkeren, M.
Poortmans, P.
Henke, G.
Anacak, Y.
Chan, S.
Landmann, C.
Kirkove, C.
Scandolaro, L.
Bernier, J.
Mirimanoff, R.O.
Ozsahin, M.

December 2017

Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...

An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center

Ulaş Solmaz
Levent Dereli
Gülşah Selvi Demirtaş
Atalay Ekin
Emre Mat
Cenk Gezer
Pınar Solmaz Hasdemir
Sevil Sayhan
Muzaffer Sancı
Niyazi Aşkar

September 2015

Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prog...

An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center [Yüksek hacimli bir kanser merkezinde uterin leiomyosarkomlu 37 olgunun analizi]

Solmaz U.
Dereli L.
Demirtaş G.S.
Ekin A.
Mat E.
Gezer C.
Hasdemir P.S.
Sayhan S.
Sancı M.
Aşkar N.

January 2015

Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and progn...

Prognostic Factors and Outcomes in 28 Cases of Uterine Leiomyosarcoma

Loizzi V
Cormio G
Nestola D
Falagario M
Surgo A
Camporeale A
Putignano G
Selvaggi L.

January 2011

Objectives: It was the aim of this study to evaluate clinicopathological characteristics and prognos...

Prognostic factors in early-stage leiomyosarcoma of the uterus.

Pelmus, M.
Penault-Llorca, F.
Guillou, L.
Collin, F.
Bertrand, G.
Trassard, M.
Leroux, A.
Floquet, A.
Stoeckle, E.
Thomas, L.
MacGrogan, G.

January 2009

Uterine leiomyosarcomas (LMSs) are rare cancers representing less than 1% of all uterine malignancie...

Oncological outcomes of unexpected uterine leiomyosarcoma: A single-center retrospective analysis of 5528 consecutive hysterectomies

Casarin J.
Ghezzi F.
Lembo A.
Artuso V.
Schivardi G.
Galati E. F.
Ambrosoli A. L.
Bogani G.
Multinu F.
Cromi A.

January 2023

Background and Methods: Uterine leiomyosarcomas (uLMS) are rare malignant tumors, often incidentally...

Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin

Oosten, Astrid
Seynaeve, Caroline
Schmitz, Paul
Bakker, Michael
Verweij, Jaap
Sleijfer, Stefan

December 2009

textabstractAlthough leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs)...

Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years\u27 clinical experience from a tertiary care center in Pakistan

Khan, Saqib Raza
Soomar, Salman Muhammad
Asghari, Tamana
Ahmed, Arsalan
Moosajee, Munira

June 2023

Background: Uterine sarcoma is an uncommon aggressive malignancy. Optimal management and prognostic ...

Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors : the result of a retrospective study of 423 cases of uterine sarcoma

Oláh, K. S.
Dunn, Janet A.
Gee, H.

July 1992

Objective To determine the survival data for the various tumour types of uterine sarcoma and determi...

Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study

Bizzarri N
Ghirardi V
Di Fiore GLM
De Iaco P
Gadducci A
Casarin J
Perrone AM
Pasciuto T
Scambia G
Fagotti A

January 2019

Uterine leiomyosarcoma (uLMS) represents a rare gynecological malignancy with high incidence of recu...

Histopathologic Prognostic Factors in Stage I Leiomyosarcoma of the Uterus: A Detailed Analysis of 27 Cases.

Wang, Wei-Lien, MD
Soslow, Robert A
Hensley, Martee
Asad, Haider, MD
Zannoni, Gian Franco
de Nictolis, Michele
Branton, Philip
Muzikansky, Alona
Oliva, Esther

April 2011

Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5...

Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients

Mancari, Rosanna
Signorelli, Mauro
Carinelli, Silvestro
De Ponti, Elena
Sesana, Silvia
Corso, Silvia
Chiappa, Valentina
Colombo, Nicoletta
Lissoni, Andrea Alberto
GADDUCCI, ANGIOLO

January 2014

Objective About 50-60% of patients with stage I-II uterine leiomyosarcoma (ULMS), primarily treated ...

Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.

Cojocaru, E
Palahepitiva Gamage, G
Butler, J
Barton, DP
Thway, K
Fisher, C
Messiou, C
Miah, AB
Zaidi, S
Gennatas, S
Benson, C
Huang, P
Jones, RL

May 2021

Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...

Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

Asano, Hiroshi
Isoe, Toshiyuki
Ito, Yoichi M.
Nishimoto, Naoki
Watanabe, Yudai
Yokoshiki, Saki
Watari, Hidemichi

March 2022

Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Althou...

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Abstract

Extracted data

Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study

Abstract

Extracted data

Related items

Related items